Chemoradiotherapy in tumours of the oesophagus and gastro-oesophageal junction

被引：10

作者：

Hulshof, M. C. C. M. ^{[1
]}

van Laarhoven, H. W. M. ^{[2
]}

机构：

[1] Acad Med Ctr, Dept Radiotherapy, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands

[2] Acad Med Ctr, Dept Med Oncol, Amsterdam, Netherlands

来源：

BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY | 2016年 / 30卷 / 04期

关键词：

Chemoradiotherapy; Oesophageal cancer; Gastro-oesophageal junction tumours; Chemotherapy; Radiotherapy; PHASE-III TRIAL; QUALITY-OF-LIFE; NEOADJUVANT CHEMORADIOTHERAPY; RESECTABLE ESOPHAGEAL; PREOPERATIVE CHEMORADIOTHERAPY; DEFINITIVE CHEMORADIOTHERAPY; PERIOPERATIVE CHEMOTHERAPY; RADIATION-THERAPY; SURVIVAL OUTCOMES; RANDOMIZED-TRIAL;

D O I：

10.1016/j.bpg.2016.06.002

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Oesophageal cancer remains a malignancy with a poor prognosis. However, in the recent 10-15 years relevant progress has been made by the introduction of chemoradiotherapy (CRT) for tumours of the oesophagus or gastro-oesophageal junction. The addition of neo-adjuvant CRT to surgery has significantly improved survival and locoregional control, for both adenocarcinoma and squamous cell carcinoma. For irresectable or medically inoperable patients, definitive CRT has changed the treatment intent from palliative to curative. Definitive CRT is a good alternative for radical surgery in responding patients with squamous cell carcinoma and those running a high risk of surgical morbidity and mortality. For patients with an out-of-field solitary locoregional recurrence after primary curative treatment, definitive CRT can lead to long term survival. (C) 2016 Published by Elsevier ltd.

引用

页码：551 / 563

页数：13

共 61 条

[31] INT 0123 (radiation therapy oncology group 94-05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy [J].

Minsky, BD ;

Pajak, TF ;

Ginsberg, RJ ;

Pisansky, TM ;

Martenson, J ;

Komaki, R ;

Okawara, G ;

Rosenthal, SA ;

Kelsen, DP .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) :1167-1174

[32]

Nabavizadeh N, 2015, GY DIS ESOPHAGUS, V5, P1

[33] Radiation therapy for loco-regionally recurrent esophageal cancer after surgery [J].

Nemoto, K ;

Ariga, H ;

Kakuto, Y ;

Matsushita, H ;

Takeda, K ;

Takahashi, C ;

Takai, Y ;

Yamada, S ;

Hosoi, Y .

RADIOTHERAPY AND ONCOLOGY, 2001, 61 (02) :165-168

[34] PREOPERATIVE RADIOTHERAPY PROLONGS SURVIVAL IN OPERABLE ESOPHAGEAL-CARCINOMA - A RANDOMIZED, MULTICENTER STUDY OF PREOPERATIVE RADIOTHERAPY AND CHEMOTHERAPY - THE 2ND SCANDINAVIAN TRIAL IN ESOPHAGEAL CANCER [J].

NYGAARD, K ;

HAGEN, S ;

HANSEN, HS ;

HATLEVOLL, R ;

HULTBORN, R ;

JAKOBSEN, A ;

MANTYLA, M ;

MODIG, H ;

MUNCKWIKLAND, E ;

ROSENGREN, B ;

TAUSJO, J ;

ELGEN, K .

WORLD JOURNAL OF SURGERY, 1992, 16 (06) :1104-1110

[35] Patterns of Recurrence After Surgery Alone Versus Preoperative Chemoradiotherapy and Surgery in the CROSS Trials [J].

Oppedijk, Vera ;

van der Gaast, Ate ;

van Lanschot, Jan J. B. ;

van Hagen, Pieter ;

van Os, Rob ;

van Rij, Caroline M. ;

van der Sangen, Maurice J. ;

Beukema, Jannet C. ;

Rutten, Heidi ;

Spruit, Patty H. ;

Reinders, Janny G. ;

Richel, Dick J. ;

Henegouwen, Mark I. van Berge ;

Hulshof, Maarten C. C. M. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (05) :385-391

[36] Adenocarcinomas of the Esophagogastric Junction Are More Likely to Respond to Preoperative Chemotherapy than Distal Gastric Cancer [J].

Reim, Daniel ;

Gertler, Ralf ;

Novotny, Alexander ;

Becker, Karen ;

zum Bueschenfelde, Christian Meyer ;

Ebert, Matthias ;

Dobritz, Martin ;

Langer, Rupert ;

Hoefler, Heinz ;

Friess, Helmut ;

Schumacher, Christoph .

ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (07) :2108-2118

[37] Patterns of recurrence in early-stage oesophageal cancer after chemoradiotherapy and surgery compared with surgery alone [J].

Robb, W. B. ;

Messager, M. ;

Dahan, L. ;

Mornex, F. ;

Maillard, E. ;

D'Journo, X. B. ;

Triboulet, J. -P. ;

Bedenne, L. ;

Seitz, J. -F. ;

Mariette, C. .

BRITISH JOURNAL OF SURGERY, 2016, 103 (01) :117-125

[38]

Ronellenfitsch U, 2013, PERIOPERATIVE CHEMOR

[39] Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial [J].

Shapiro, Joel ;

Van Lanschot, J. Jan B. ;

Hulshof, Maarten C. C. M. ;

van Hagen, Pieter ;

Henegouwen, Mark I. van Berge ;

Wijnhoven, Bas P. L. ;

van Laarhoven, Hanneke W. M. ;

Nieuwenhuijzen, Grard A. P. ;

Hospers, Geke A. P. ;

Bonenkamp, Johannes J. ;

Cuesta, Miguel A. ;

Blaisse, Reinoud J. B. ;

Busch, Olivier R. C. ;

ten Kate, Fiebo J. W. ;

Creemers, Geert-Jan M. ;

Punt, Cornelis J. A. ;

Plukker, John Th M. ;

Verheul, Henk M. W. ;

Bilgen, Ernst J. Spillenaar ;

van Dekken, Herman ;

van der Sangen, Maurice J. C. ;

Rozema, Tom ;

Biermann, Katharina ;

Beukema, Jannet C. ;

Piet, Anna H. M. ;

van Rij, Caroline M. ;

Reinders, Janny G. ;

Tilanus, Hugo W. ;

Steyerberg, Ewout W. ;

van der Gaast, Ate .

LANCET ONCOLOGY, 2015, 16 (09) :1090-1098

[40] Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis [J].

Sjoquist, Katrin M. ;

Burmeister, Bryan H. ;

Smithers, B. Mark ;

Zalcberg, John R. ;

Simes, R. John ;

Barbour, Andrew ;

Gebski, Val .

LANCET ONCOLOGY, 2011, 12 (07) :681-692

← 1 2 3 4 5 6 7 →